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Mineralocorticoid Receptor
Antagonists in the Treatment of
Coronary Artery Disease,
Myocardial Infarction and Heart
Failure
Carolin Zwadlo and Johann Bauersachs
Abstract
Affecting sodium reabsorption and potassium excretion in the kidney,
mineralocorticoid receptor antagonists (MRA) were originally developed as
antihypertensive drugs. After several large clinical trials, the concept of MR
blockade has nowadays become a main treatment paradigm in heart failure with
reduced ejection fraction (HFrEF) and for patients after myocardial infarction (MI)
with left ventricular (LV) dysfunction. Recent analyses also point to a beneficial
effect of early MRA treatment in patients with acute MI without LV dysfunction,
however, there is no clear evidence yet. Although promising data from preclinical
settings suggest that MRAs mediate favorable anti-atherogenic effects, clinical
studies in patients with stable coronary artery disease (CAD) have not been able to
detect differences of hard clinical outcomes. The concept might still be pursued
using the most recent MRA, like the non-steroidal MR antagonist finerenone, and
larger clinical trials need to be performed. Here, we review the current impact of
MRA in patients with CAD and focus on the conflicting evidence of preclinical
and clinical data in patients with stable CAD and preserved ejection fraction and
summarize the current indications for MRA in these patients according to the
guidelines.
Keywords: mineralocorticoid receptor antagonists (MRA), aldosterone,
heart failure, myocardial infarction, spironolactone, eplerenone, finerenone
1. Introduction
Because of their effect on sodium reabsorption and potassium excretion in the
kidney, mineralocorticoid receptor antagonists (MRA) were originally developed as
antihypertensive drugs. Over the years, it became clear that their influence on the
cardiovascular system is much broader than initially thought. Spironolactone
was the first MRA to be developed. Later, eplerenone followed. Nowadays,
mineralocorticoid receptor (MR) antagonism consists of the steroidal first- and
second-generation MRAs spironolactone and eplerenone and the non-steroidal
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third-generation MRAs, such as finerenone, the latter one not being in clinical use
outside studies yet.
After several large clinical trials, the concept of MR blockade has become a main
treatment paradigm with chronic heart failure with reduced ejection fraction
(HFrEF) and for patients after myocardial infarction (MI) with left ventricular (LV)
dysfunction. On the contrary, no general recommendation for immediate MR antag-
onism in patients without LV dysfunction is currently justified. Moreover, there are
controversial data on the role of MRA in stable coronary artery disease (CAD),
although high plasma aldosterone levels have been associated with increased mortal-
ity and ischemic events in patients with stable CAD with or without heart failure.
Preclinical studies underline the anti-atherogenic and favorable vascular effects of
spironolactone, eplerenone and finerenone via various mechanisms. These positive
results, however, are largely limited to animal models and clinical studies could not
confirm an improvement of markers of vascular health so far.
In the past, we have summarized the existing preclinical and clinical data on
spironolactone and eplerenone in the treatment of CAD and its related complica-
tions [1]. Here, we review the impact of MRAs in these patients and supplement
updated information on published clinical studies and especially the newly
developed third-generation MRA, finerenone. We aim to shed light on the current
conflicting evidence of preclinical and clinical data and summarize the indications
for MR antagonism in patients with CAD and its complications.
2. Main part
2.1 Effects of aldosterone
The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and
fluid and electrolyte balance under physiological and pathological conditions. Aldo-
sterone is the final product of the RAAS. It is a steroid hormone produced by zona
glomerulosa cells in the adrenal cortex. Traditionally, its action was thought to be
restricted to sodium reabsorption and potassium excretion via activation of the
cytosolic MR in epithelial cells of the distal colon, the renal nephron as well as
salivary and sweat glands. However, over time it became clear that aldosterone’s
action is much broader than initially thought and MRs were identified in vascular
endothelial and smooth muscle cells as well as in cardiomyocytes, endothelial cells,
fibroblasts and macrophages in the heart [2].
Key evidence for the role of MR in the pathophysiology of cardiac diseases was
derived from cell-specific overexpression and deletion studies. In mouse models of
chronic pressure overload andmyocardial infarction, deletion or inactivation of theMR
gene attenuated left ventricular dilatation, cardiac hypertrophy and development of
heart failure, whereas overexpression of theMR in cardiomyocytes induced ventricular
remodeling, development of heart failure and pro-arrhythmogenic effects [3–7].
Aldosterone and glucocorticoids bind with similar affinity to MR. In the normal
state, plasma glucocorticoid levels are more than 100 times higher that aldosterone
levels and the majority of MRs in the heart is occupied by glucocorticoids. In
patients with acute MI and chronic heart failure, not only circulating aldosterone
levels but also aldosterone biosynthesis is enhanced. Moreover, the aldosterone-MR
complex is more stable than the glucocorticoid-MR complex [8, 9]. Based on these
findings, it is nowadays well accepted that aldosterone contributes to endothelial
dysfunction, fibrinolytic disorders, inflammation, oxidative stress, fibrosis and
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hypertrophy leading to or at least aggravating cardiovascular diseases (CVD) such
as CAD and heart failure [10–13].
Presumably, the exact molecular mechanism of aldosterone’s action is still not
fully understood and appears to be more complex than initially thought. For exam-
ple, aldosterone has been shown to promote the formation of venous thrombosis in
normotensive rats via mechanisms involving primary hemostasis, fibrinolysis, nitric
oxide and oxidative stress-dependent pathways but MR blockade was insufficient to
reverse the effect. Notably, other receptors, such as the glucocorticoid receptor
(GR) and angiotensin II receptor type 1 are involved [14, 15]. The effects of aldo-
sterone are mediated via classic nuclear receptors (genomic actions of aldosterone)
and cell-membrane receptors (non-genomic actions of aldosterone) with alternative
pathways, including activation of protein kinases or secondary messenger signaling
cascades [16, 17]. Indeed, in high, non-physiological plasma conditions, aldosterone
can also act via GR [18] or the G protein-coupled estrogen receptor (GPR30).
The latter one plays an important role in aldosterone-mediated regulation of
endothelial cell growth and in aldosterone’s endothelial-mediated regulation of
vasoreactivity [19].
2.2 Development of MRAs
The development of MRAs begun during the 1950s. At that time, the main role
of aldosterone was considered to be renal sodium and potassium excretion.
Spironolactone, the first steroidal MRA, was primarily developed and used for the
medical control of edema and ascites and control blood pressure, respectively. With
the RALES trial, the perception of spironolactone changed; spironolactone, in addi-
tion to standard therapy, substantially reduced the risk of both morbidity and death
among patients with severe heart failure [20]. With eplerenone, a second-
generation steroidal MRA was developed. The advantage of eplerenone compared
to spironolactone is mainly the higher selectivity for mineralocorticoid receptors,
therefore avoiding hormonal side effects such as gynecomastia. Despite consider-
able efforts to ensure a broad application of this essential medication in this defined
patient collective, many clinicians were reluctant to employ MRAs in their clinical
practice due to potential side effects. These side effects included worsening of renal
function, hyperkalemia and gynecomastia.
Interestingly, Vukadinović et al. performed a meta-analysis. The authors
emphasize that non-MRA-related rises in potassium levels might be underestimated
and should be rigorously explored before cessation of the evidence-based therapy
with MRAs [21].
Nevertheless, the issue of hyperkalemia and worsening renal function triggered
several pharmaceutical companies to develop novel MR-antagonizing compounds.
These so-called third-generation MRAs, such as finerenone or canrenone, are non-
steroidal compounds with both high selectivity and high potency to inhibit MR. The
first compound of these novel MRAs undergoing clinical evaluation was finerenone,
formerly known as BAY 94-8862. Finerenone is even more selective than
eplerenone to the MR with very low affinity to androgen, glucocorticoid and pro-
gesterone receptor. In clear contrast to spironolactone and eplerenone, which have a
higher tendency to concentrate in the kidney, finerenone displays a balanced dis-
tribution pattern into cardiac and kidney tissue of healthy rats [22, 23]. This sug-
gests a more favorable balance between cardioprotection and renal side effects,
especially in populations prone to hyperkalemia such as patients with chronic kid-
ney disease or diabetes (Figure 1) [24, 25].
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To date, finerenone is under investigation in two large clinical trials (FIGARO-
DKD: A Randomized, Double-Blind-Placebo-controlled, Multicenter, Event-driven
Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of
Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus
and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of
Care (NCT02545049) and FIDELIO-DKD: A Randomized, Double-Blind, Placebo-
controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate
the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the
Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the
Clinical Diagnosis of Diabetic Kidney Disease (NCT02540993)). The effect of
canrenone compared to other therapies on cardiovascular mortality in patients with
chronic heart failure and preserved systolic function is currently undertaken in the
“COFFEE-IT” study: “CanrenOne eFFects on cardiovascular mortality in patiEnts
with congEstIve hearT failure” (https://clinicaltrials.gov/ct2/show/NCT03263962).
2.3 MRAs in chronic systolic LV dysfunction (after ischemia)
For a long time, the strongest evidence for the clinical usefulness of MRAs
existed for patients with chronic heart failure NYHA III and reduced ejection
fraction. In 2012, the guidelines for diagnosis and treatment of acute and chronic
heart failure by the European Society of Cardiology amended the recommendation
of MRAs for all patients with symptoms of heart failure class II and worse according
to the New York Heart Association (NYHA)-classification and an ejection fraction
≤35% [26]. Since then, the concept of MR blockade has become a main treatment
paradigm in HFrEF.
Two large clinical trials have firmly established the role of MRAs in chronic heart
failure: the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone
in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-
HF). Death from all causes and specifically cardiac death as well as hospitalization
due to heart failure were decreased proving the efficacy of MRAs in patients with
severely reduced LV function [20, 27]. Although the underlying pathophysiology is
complex, the clinical effects of MRAs in these patients are thought to be mainly
related to the improvement of LV remodeling with a reduction in collagen synthesis
and myocardial fibrosis, seen as a decrease in LV size and hypertrophy and
improved LV function [28].
Figure 1.
Characteristics of three generations of mineralocorticoid receptor antagonists (MRAs).
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With the development of the third-generation MRAs, such as finerenone, there
came the necessity for further clinical trials. In rats with deoxycorticosterone
acetate-(DOCA)/salt-induced heart and kidney injury as well as in a chronic
myocardial infarction rat model, finerenone had proved to reduce cardiac hyper-
trophy, NT-proBNP and proteinuria more efficiently than eplerenone when directly
comparing equinatriuretic doses [29]. Similarly, in a mouse model of pressure
overload-induced heart failure treatment with finerenone compared to head-to-
head with eplerenone resulted in a more pronounced prevention of myocardial
hypertrophy [30].
ARTS (MinerAlocortocoid Receptor antagonist Tolerability Study) was the first
randomized, controlled, phase II trial to test the safety and tolerability (Part A) of
oral finerenone, at that time still under the name BAY 94-8862, in comparison with
placebo and spironolactone (Part B). Finerenone was associated with significantly
less increases in serum potassium concentration and fewer incidences of
hyperkalemia (5.3 and 12.7%, respectively). Moreover, it decreased the levels of
BNP, NT-proBNP and albuminuria at least as much as spironolactone. Adverse
events related to the substance were infrequent and mostly mild. The authors
concluded that in patients with HFrEF and moderate CKD, finerenone in various
concentrations was at least as effective as spironolactone in decreasing biomarkers
of hemodynamic stress and was associated with lower incidences of hyperkalemia
[31, 32]. After these promising results, ARTS-HF (MinerAlocortocoid Receptor
antagonist Tolerability Study-Heart Failure), a randomized, double-blind, phase IIb
multicenter study was initiated to evaluate oral doses of finerenone given in
patients with worsening heart failure and reduced ejection fraction and chronic
kidney disease and/or diabetes mellitus. The trial showed a comparable efficacy
between all dosage groups of finerenone and eplerenone in the primary endpoint,
the decrease of >30% in plasma NT-proBNP from baseline to day 90 [33]. Similar
results were obtained in the relatively small ARTS-HF Japan trial, conducted in
Japan with the same regime as described for ARTS-HF [34]. Overall, finerenone
showed a promising safety and efficacy profile in the so far conducted trials. How-
ever, patient numbers are too small to draw any fundamental conclusions. With
FINESSE-HF, a multicenter, randomized, double-blind, double-dummy, parallel-
group, active-controlled study to evaluate the efficacy and safety of finerenone
compared to eplerenone on morbidity and mortality in patients with chronic heart
failure and reduced ejection fraction after recent heart failure. Decompensation and
additional risk factors was supposed to launch. However, the trial prematurely
ended in May 2016 (https://www.clinicaltrialsregister.eu/ctr-search/trial/
2015-002168-17/HU#D). To date, finerenone holds its promise of a novel MRA with
greater selectivity, greater potency and fewer side effects. However, further clinical
trials with enough power are needed in patients.
Currently, two clinical trials are evaluating the efficacy and safety of finerenone
in patients with type 2 diabetes mellitus and diabetic kidney disease: the FIGARO-
DKD and FIDELIO-DKD trial. Both trials evaluate whether oral finerenone com-
pared to placebo is effective and safe in addition to standard of care. The primary
outcome measures are, however, different. FIGARO-DKD evaluates the time of the
first occurrence of the composite endpoint of cardiovascular death and non-fatal
cardiovascular events (myocardial infarction, stroke or hospitalization for heart
failure) in a follow-up of up to 53 months. The study is still recruiting and a total
enrollment of 6400 participants with primary completion in January 2020 is esti-
mated (https://clinicaltrials.gov/ct2/show/NCT02545049). FIDELIO-DKD aims to
investigate the time of the first occurrence of the composite endpoint of onset of
kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR)
≥40% from baseline over at least 4 weeks and renal death in a follow-up of up to
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48 months. A total of 4800 participants and a study completion date of October
2019 is estimated (https://clinicaltrials.gov/ct2/show/NCT02540993).
2.4 MRAs early post infarction
Several preclinical animal studies with coronary artery disease and/or with heart
failure have provided substantial evidence that activation of MR plays a pivotal role
in cardiac healing and remodeling after myocardial ischemia. These studies
suggested that cardiomyocyte-specific deletion of the MR gene attenuates LV dila-
tation, hypertrophy, fibrosis and heart failure, whereas cardiomyocyte-specific MR
overexpression induced adverse remodeling and pro-arrhythmogenic effects [3, 7].
Moreover, administration of MRAs early after MI reduced the expansion of the
healing infarct, attenuated early left ventricular dilatation and dysfunction and had
more beneficial effects on survival, early cardiac dilatation and functional decline
[3, 7, 35–38]. Indeed, after an acute MI, not only circulating aldosterone levels are
increased but also the myocardium distant from the infarct zone shows enhanced
activation of aldosterone synthesis [36].
In the clinical setting, Hayashi et al. demonstrated in 2003 that in patients with
their first anterior STEMI and no evidence of early heart failure, intravenous
canrenone followed by oral spironolactone for 6 months beginning day one post-MI
was safe and associated with a significant reduction in ventricular remodeling,
myocardial fibrosis and inflammatory cytokine activation [39]. In the same year,
the well-planned and executed Eplerenone Post-acute myocardial infarction Heart
failure Efficacy and Survival Study (EPHESUS) demonstrated MR blockade to
substantially improve morbidity and mortality among patients with moderate to
severe heart failure and LV dysfunction after MI [40]. More than 3000 patients
with an ejection fraction <40% received either 50 mg eplerenone or placebo on a
daily basis, starting 3–14 days after MI. In comparison to the placebo-group, all-
cause mortality, cardiovascular mortality and sudden cardiac death were decreased
by 15, 17 and 21%, respectively, in the eplerenone group.
Although EPHESUS had clearly established the clinical efficacy of MRAs in
patients with heart failure after an acute MI, the value of MRAs after MI without
concomitant heart failure needed to be determined. Moreover, EPHESUS suggested
that an early initiation of eplerenone treatment had significant beneficial effects
compared to later initiation [41]. The REMINDER trial (Role of Eplerenone in acute
Myocardial Infarction-Double-blind, Early treatment initiation, Randomized,
placebo-controlled, multi-center study) evaluated the potential benefit of early
administered eplerenone on cardiovascular morbidity and mortality after STEMI. In
this randomized, placebo-controlled, double-blind trial, 1012 patients with acute
STEMI and without a history of heart failure were randomized to receive either
eplerenone (25–50 mg once daily) or placebo in addition to standard therapy.
Treatment was initiated within 24 hours after onset of symptoms. The primary
endpoint was the composite of CV mortality, re-hospitalization or extended initial
hospital stay, due to diagnosis of heart failure, sustained ventricular tachycardia or
fibrillation, ejection fraction ≤40% or elevated BNP/NT-proBNP at 1 month or
more after randomization. The trial showed that the addition of eplerenone during
the acute phase of STEMI was safe and well tolerated. It reduced the primary
endpoint over a mean 13 months follow-up mostly because of significantly lower
natriuretic peptide levels [42].
Similarly, the ALBATROSS trial (Aldosterone Lethal effects Blocked in Acute
myocardial infarction Treated with or without Reperfusion to improve Outcome
and Survival at 6 months follow-up) randomized patients admitted for STEMI and
non-STEMI to test whether administration of MRAs within 72 hours after onset of
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symptoms improves cardiovascular outcome regardless of heart failure and treat-
ment strategy. In total, 1603 patients were included an received an MRA regime
with a single 200 mg intravenous bolus of potassium canrenoate followed by 25 mg
oral spironolactone once daily for 6 months in addition to standard therapy or
standard therapy alone. The primary outcome of the study was the composite of
death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for
implantable defibrillator, or new or worsening heart failure at 6-month follow-up.
Key secondary/safety outcomes included death and other individual components of
the primary outcome and rates of hyperkalemia at 6 months [43]. However, the
study failed to show the benefit of early MRA use in addition to standard therapy in
patients admitted for MI, and was intensively discussed among experts. In the
overall opinion, both ALBATROSS and REMINDER are undersized to detect a
difference in rates of hard clinical outcomes [43, 44]. Beygui et al. therefore
conducted a pre-specific meta-analysis and pooled individual patient-level data of
the STEMI subgroup of the ALBATROSS and the total population of the
REMINDER trial. Their analysis showed reduced rates of death in the MRA-treated
group compared to standard therapy. Although the authors underline that this
specific subgroup analysis should be considered “exploratory,” it suggests a consis-
tent effect of the early MRA-treatment in patients with STEMI [45]. However,
under these circumstances, additional studies are needed to clarify the role of early
use of MRAs in patients with MI without heart failure.
2.5 MRAs in stable coronary artery disease
A large number of preclinical studies indicate that aldosterone is an important
stimulus for vascular disease, with inflammation and fibrosis being the key players,
[3–6] and MRAs are able to inhibit atherosclerosis progression in different animal
models [46–49]. Treatment with aldosterone results in increased inflammation and
upregulated expression of proinflammatory cytokines, such as tumor necrosis
factor-α, interleukin-1β and transforming growth factor-β1 in rat myocardium.
Additionally, it leads to an increase in myocardial collagen synthesis and content,
fibrosis and profibrotic factors, including connective tissue growth factor, TGF-β,
plasminogen activator inhibitor-1, matrix metalloproteinase-2 and tumor necrosis
factor-α [7]. Oxidative stress is well-recognized to trigger inflammation and to
contribute to the development of fibrosis [7]. Furthermore, MR activation stimu-
lates apoptosis and causes vasoconstriction and reduced blood flow in the animal
heart and MRA treatment reverses these effects [7]. Especially finerenone can
significantly reduce apoptosis of endothelial cells and simultaneously attenuate
smooth muscle cells proliferation, resulting in accelerated endothelial healing and
reduced neointima formation of the injured vessels [50]. Over the years, several
clinical studies in patients with coronary artery disease pinpointed the association of
high aldosterone levels with an increased risk of cardiovascular death and all-cause-
mortality [51], the occurrence of an ischemic event [52] or the progression of
carotid artery plaques [53]. Although clear evidence exists that there is a strong
relationship between aldosterone and the progression of chronic CAD, up to now no
large clinical trial has specifically evaluated the effect of MRAs on the amelioration
of plaque formation. Vukusich et al. executed a randomized, double-blind, placebo-
controlled trial to assess the effectiveness of spironolactone in preventing progres-
sion of carotid intima-media thickness (CIMT) in non-diabetic hemodialysis
patients. Over a period of 24 months, 53 patients received either 50 mg
spironolactone or placebo thrice weekly after dialysis. CIMT measurements
revealed a progression in the placebo-group whereas in the spironolactone-treated
patients, CIMT significantly decreased [54]. Another clinical trial is currently
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recruiting patients to study the effect of spironolactone on vascular atherosclerotic
burden. The “Mineralocorticoid Receptor Antagonism Clinical Evaluation in ath-
erosclerosis Trial” (NCT02169089) is a phase IV trial that aims to evaluate the
efficacy of spironolactone in decelerating the worsening of atherosclerotic disease in
the aorta in patients with type 2 diabetes and a previous history of CAD. The
patients are randomized to spironolactone (12.5–25 mg daily) versus placebo. The
primary endpoint is the atheroma volume evaluated via magnetic resonance imag-
ing (MRI) pictures of the aortic wall before and after therapy (https://www.clinica
ltrialsregister.eu/ctr-search/trial/2015-002168-17/HU#D). In another clinical
approach, Garg et al. measured the effect of spironolactone on cardiovascular func-
tion in patients with diabetes and used the coronary flow reserve as a marker for
coronary microvascular function. A total of 64 participants with well-controlled
diabetes who were on chronic ACE-therapy were randomized to 25 mg
spironolactone, 12.5 mg hydrochlorothiazide or placebo for 6 months. The
spironolactone-treated patients showed a significant improvement in coronary
microvascular function [55].
Endothelial dysfunction plays an important role in the pathogenesis of CAD and
is a well-established marker for cardiovascular risk and prognosis [56]. Accordingly,
MR blockade has been shown to improve endothelial dysfunction in patients with
HFrEF [57]. Bavry et al. designed a double-blind, parallel-group, repeated measures
study in women with symptoms and signs of ischemia and coronary endothelial
dysfunction but no significant CAD already receiving ACE-inhibitor or angiotensin
receptor blockers. Patients received either eplerenone (25 mg daily for 4 weeks,
then uptitrated to 50 mg daily for 12 weeks) or placebo. The primary outcome was
percent change in coronary diameter to acetylcholine and secondary in flow reserve
to adenosine at 16 weeks. A total of 41 women completed the treatment period, but
there was no significant difference between treatment groups [58]. Similarly,
Sudano et al. randomized CAD patients with preserved ejection fraction to receive
daily eplerenone (25 mg) or placebo and assessed endothelial cell function after
4 weeks of treatment. Based on brachial artery dilatation, the investigators did not
find any differences in the endothelial cell function between the groups [59].
In contrast to the firmly established benefit of MR blockade in HFrEF and
patients with LV-dysfunction after MI, the role of MRAs with stable CAD with
preserved ejection fraction remains a matter of debate. The variety of small studies
with different approaches and endpoints is not sufficient to give a general recom-
mendation. Larger, prospective, randomized trials are needed further evaluating
the role of MR blockade in stable CAD.
3. Conclusion
It has long been clear that the effects of aldosterone are more diverse than
originally thought. High aldosterone plasma levels early after STEMI or NSTEMI or
in patients with heart failure are associated with increased cardiovascular morbidity
and mortality. Clinical trials have firmly established that MR blocking therapy pro-
vides considerable improvements in cardiovascular mortality and morbidity in
patients with severe heart failure (RALES and ARTS-HF), LV dysfunction after
acute MI (EPHESUS), as well as in patients with less symptomatic chronic heart
failure (EMPHASIS-HF) (Table 1). With REMINDER and ALBATROSS, there is
conflicting data on the role of MRAs in patients after MI without LV-dysfunction.
However, one has to keep in mind that ALBATROSS and REMINDER were both
underpowered and group analysis showed that patients with STEMI might benefit
from treatment. As with stable CAD and preserved ejection fraction, the role of MR
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Study RALES EPHESUS EMPHASIS-
HF
REMINDER ALBATROSS ARTS ARTS-HF ARTS-HF
Japan
FIGARO-
DKD
FIDELIO-
DKD
Year 1999 2003 2011 2014 2016 2013 2015 2016 Recruiting Active, not
recruiting
Primary
end-point
Mortality All-cause
or CV
mortality,
hosp. for
CHF
CV death,
hosp. for
CHF
Mortality,
hosp. for
CHF
Death,
worsened
CHF,
arrhythmias
Part A: safety and
tolerability; Part
B: change in
serum potassium
decrease in NT-
proBNP >30%
decrease in
NT-proBNP
>30%
CV death and
no-fatal CV
events
Onset of
kidney failure,
decrease of
eGFR
No. of
patients
1663 6642 2737 506 1603 65 (Part A) +393
(Part B)
1066 72 6400
(estimated)
4800
(estimated)
Inclusion
criteria
Severe CHF Post-MI
(within 3–
14 days),
CHF or
diabetes
Mild CHF,
<55 years
STEMI STEMI or high
risk non-
STEMI,
≥18 years
HFrEF and mild
(Part A)/
moderate (Part
B) chronic
kidney disease
Worsening CHF,
treatment with
diuretics; eGFR
≥30 ml/min/m2
Worsening
CHF,
treatment
with diuretics;
eGFR ≥30 ml/
min/m2
Type 2
Diabetes
mellitus,
Diabetic
Kidney
Disease,
pretreatment
with ACE-I
Type 2
Diabetes
mellitus,
Diabetic
Kidney
Disease,
pretreatment
with ACE-I
NYHA III-IV NYHA I-IV NYHA II n.a. n.a. NYHA II-III n.a. n.a. n.a. n.a.
EF <35% EF <40% EF <35% EF >40% n.a. EF ≤40% EF ≤40% EF ≤40% n.a. n.a.
Major
exclusion
criteria
P-creatinine
>220 μm, P-K
>5.0
P-
creatinine
>220 μm,
P-K >5.0
eGFR <
30 ml/min/
m2, P-K >5.0
eGFR <
30 ml/min/
m2, P-
creatinine
≥220 μm
P-creatinine
>220 μm and/
or Creatinine
clearance <
30 ml/m
worsening HF
requiring
hospitalization/
treatment with
diuretucs
de novo HF, acute
inflammation, ACS/
stroke 3 months prior
de novo HF,
acute
inflammation,
ACS/stroke
3 months prior
HFrEF, NYHA
II-IV, Dialysis
HFrEF, NYHA
II-IV, Dialysis
Mean age
(years  SD)
65  12 64  12 68.7  7.7 58.5  10.8 58 69.2 – 72.5  9.7 – 10.6
(different treatment
groups)
65.9 – 78.2
(different
treatment
groups)
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Study RALES EPHESUS EMPHASIS-
HF
REMINDER ALBATROSS ARTS ARTS-HF ARTS-HF
Japan
FIGARO-
DKD
FIDELIO-
DKD
Medical
therapy
ACE-I,
diuretic
ACE-I/
ARB, ß-
blocker,
diuretic
ACE-I/ARB,
ß-blocker,
diuretic
ACE-I/ARB,
ß-blocker
ACE-I/ARB, ß-
blocker
ACE-I/ARB, ß-
blocker, diuretic
ACE-I/ARB, ß-blocker,
diuretic
ACE-I/ARB,
ß-blocker,
diuretic
ACE-I ACE-I
MRA Spironolactone Eplerenone Eplerenone Eplerenone Bolus of K+
canreonate,
then
spironolactone
Finerenone
versus
Spironolactone
versus Placebo
Finerenone versus
Eplerenone
Finerenone
versus
Eplerenone
Finerenone Finerenone
Dose (mg/
day)
25–50 25–50 25–50 Up to 50 25 2.5–10
(Finerenone); up
to 50 mg
(Spironolactone)
2.5–20 (Finerenone);
up to 50 mg
(Eplerenone)
2.5–20
(Finerenone);
up to 50
(Eplerenone)
10 and 20 mg 10 and 20 mg
Mean daily
dose
(mg/day)
26 43 39 88.6%
received
high dose
25 % % %
Follow-up 24 months 16 months 21 months 18 months 6 months 1 month 90 days 90 days 53 months 48 months
End-point 30% all-
cause
mortality
15% all-
cause
mortality
34% all-
cause
mortality
composite
clinical
endpoint:
eplerenone
1.8%,
placebo
3.2%
primary
outcome:
spironolactone
11.8%, placebo
12.2%
Part A: safety and
tolerabilty
confirmed; Part
B: lower
incidences of
hyperkalaemia
37.2% eplerenone;
30.9–38.8% finerenone
23.1%
eplerenone;
15.4–45.5%
finerenone
31%
cardiovasc.
mortality
17%
cardiovasc.
mortality
37%
cardiovasc.
mortality
33% hosp.
for HF
23%
hosp. for
HF
42% hosp.
for HF
Table 1.
Trials of mineralocorticoid receptor antagonists in the context of myocardial infarction and heart failure: demographics and outcome.
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blockade in this highly inhomogeneous patient collective is still unclear and remains
a matter of debate. The variety of small studies with different approaches and
endpoints is not sufficient to give a general recommendation. Larger, prospective,
randomized trials are urgently needed.
Regarding drug safety and side effects: when contraindications such as co-
medication with potassium-sparing diuretics are respected and renal function and
potassium levels are closely monitored, application of spironolactone and
eplerenone is relatively safe and patients with mild to moderate renal insufficiency
gain similar reductions in mortality and hospitalization as heart failure patients with
normal renal function. Nevertheless, there are always cases in which deterioration
of the kidney function or hyperkalemia requires the discontinuation of the medica-
tion. Especially with the development of the non-steroidal third-generation MRAs,
such as finerenone, with both high selectivity and high potency to inhibit MR, we
might be able to fulfill the hope of achieving cardiovascular benefit without or at
least with fewer renal side effects than spironolactone and eplerenone (Figure 1).
Without any question, MRAs are nowadays one of the mainstays of current
pharmacotherapy for cardiovascular diseases and are clearly indicated in patients
with chronic heart failure (NYHA class II–IV and and/or an ejection fraction ≤35%)
as well as in patients with evidence of heart failure/LV dysfunction early after an
acute MI. On the contrary, no general recommendation for immediate MR antago-
nism is currently justified in patients without LV dysfunction after MI. An ade-
quately powered prospective randomized trial evaluating the safety and efficacy of
MRA administration early post-MI in patients without heart failure/LV dysfunction
is still needed to finally answer that question.
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